Heras M, Bueno H, Bardají A, Fernández-Ortiz A, Martí H, Marrugat J
Department of Cardiology of Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Heart. 2006 Nov;92(11):1571-6. doi: 10.1136/hrt.2005.079673. Epub 2006 Apr 27.
To analyse intensity of treatment of high-risk patients with non-ST elevation acute coronary syndromes (NSTEACS) included in the DESCARTES (Descripción del Estado de los Sindromes Coronarios Agudos en un Registro Temporal Español) registry.
Patients with NSTEACS (n = 1877) admitted to 45 randomly selected Spanish hospitals in April and May 2002 were studied.
Patients with ST segment depression and troponin rise were considered high risk (n = 478) and were compared with non-high risk patients (n = 1399).
46.9% of high-risk patients versus 39.5% of non-high-risk patients underwent angiography (p = 0.005), 23.2% versus 18.8% (p = 0.038) underwent percutaneous revascularisation, and 24.9% versus 7.4% (p < 0.001) were given glycoprotein IIb/IIIa inhibitor. In-hospital and six-month mortality were 7.5% versus 1.1% and 17% versus 4.6% (p < 0.001), respectively. A treatment score (> or = 4, 2-3 and < 2) was defined according to the number of class I interventions recommended in clinical guidelines: aspirin, clopidogrel, beta blockers, angiotensin-converting enzyme inhibitors, statins and revascularisation. Independent predictors of six-month mortality were age (odds ratio (OR) 1.07, 95% confidence interval (CI) 1.04 to 1.10, p < 0.001), diabetes (OR 1.92, 95% CI 1.14 to 3.22, p = 0.014), previous cardiovascular disease (OR 4.17, 95% CI 1.63 to 10.68, p = 0.003), high risk (OR 2.20, 95% CI 1.30 to 3.71, p = 0.003) and treatment score < 2 versus > or = 4 (OR 2.87, 95% CI 1.27 to 6.52, p = 0.012).
Class I recommended treatments were underused in high-risk patients in the DESCARTES registry. This undertreatment was an independent predictor of death of patients with an acute coronary syndrome.
分析纳入DESCARTES(西班牙急性冠状动脉综合征时间登记研究)登记研究的非ST段抬高型急性冠状动脉综合征(NSTEACS)高危患者的治疗强度。
对2002年4月和5月入住45家随机选取的西班牙医院的NSTEACS患者(n = 1877)进行研究。
将ST段压低且肌钙蛋白升高的患者视为高危患者(n = 478),并与非高危患者(n = 1399)进行比较。
46.9%的高危患者接受了血管造影,而非高危患者为39.5%(p = 0.005);23.2%的高危患者接受了经皮血管重建术,非高危患者为18.8%(p = 0.038);24.9%的高危患者使用了糖蛋白IIb/IIIa抑制剂,非高危患者为7.4%(p < 0.001)。住院死亡率和6个月死亡率分别为7.5%对1.1%以及17%对4.6%(p < 0.001)。根据临床指南推荐的I类干预措施数量定义了一个治疗评分(≥4、2 - 3和<2):阿司匹林、氯吡格雷、β受体阻滞剂、血管紧张素转换酶抑制剂、他汀类药物和血管重建术。6个月死亡率的独立预测因素为年龄(比值比(OR)1.07,95%置信区间(CI)1.04至1.10,p < 0.001)、糖尿病(OR 1.92,95% CI 1.14至3.22,p = 0.014)、既往心血管疾病(OR 4.17,95% CI 1.63至10.68,p = 0.003)、高危(OR 2.20,95% CI 1.30至3.71,p = 0.003)以及治疗评分<2对比≥4(OR 2.87,95% CI 1.27至6.52,p = 0.012)。
在DESCARTES登记研究中,I类推荐治疗在高危患者中未得到充分应用。这种治疗不足是急性冠状动脉综合征患者死亡的独立预测因素。